+0.15 (+7.32%)
Dilution Risk
25%R&D Expenses
3.20 M
Operating CF
-4.57 M
Total Assets
27.30 M
Total Liabilities
9.67 M
Equity
17.63 M
D/E Ratio
12,345
Cash Position
24.53 M
Monthly Burn
1.52 M
Runway
15 mo
Burn Trend
StableSEC Filing
May 14, 2026locked
| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SER-252 Small molecule | PARKINSON DISEASE (Disorder) | Phase 1 | NCT07422675 | 5% | $28M | RECRUITING | 40 | STALLED | D (23) | Jan 1, 2027 | MODERATE_RISK | LOW May 24, 2026 |
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Serina Therapeutics has received acceptance from NYSE American for its compliance plan to meet listing standards. The company aims to regain compliance by July 2027 while continuing its SER-252 clinical program. However, it faces challenges due to previous financial losses and low stockholders' equity.
Read more →Serina Therapeutics reported its financial results for 2025, highlighting significant advancements including FDA clearance for SER-252 and the initiation of its Phase 1b trial for Parkinson's disease. The company secured up to $30 million in financing, enhancing its clinical and financial position. However, it also reported an increased net loss and rising operating expenses.
Read more →Serina Therapeutics will present at the 38th Annual Roth Conference on March 24, 2026. CEO Steve Ledger will discuss the company's proprietary POZ Platform™ technology and its applications in treating neurological diseases. The presentation will be available via live webcast and archived for 90 days. The POZ technology aims to enhance drug delivery and efficacy.
Read more →Serina Therapeutics has initiated dosing in its Phase 1b registrational trial for SER-252, targeting advanced Parkinson's disease. The trial aims to assess the safety and efficacy of SER-252, which utilizes the company's proprietary POZ Platform™. With FDA alignment on its regulatory pathway, Serina is positioned to generate critical clinical data.
Read more →Serina Therapeutics, a clinical-stage biotechnology company, announced that its CEO, Steven Ledger, will present at a webinar titled 'Navigating the New FDA Era: 2026 Strategic Priorities and the Future of Life Sciences' on February 4, 2026. The event will allow participants to ask questions directly to the CEO. Registration is available through Tribe Public's website.
Read more →Serina Therapeutics has received FDA clearance for its IND application for SER-252, an investigational therapy aimed at treating advanced Parkinson's disease. This clearance enables the company to start regulatory activities and initiate a Phase 1b clinical study. The CEO emphasized the importance of this milestone and the potential of SER-252 to meet significant medical needs.
Read more →Serina Therapeutics has submitted a complete response to the FDA regarding the clinical hold on its SER-252 program for advanced Parkinson's disease. The FDA's hold was due to requests for additional information on a formulation excipient. The company is actively preparing for a Phase 1b study, aiming for the first patient to be enrolled in early 2026, pending FDA feedback.
Read more →